33.70 0.00 (0.00%)
After hours: 4:55PM EDT
|Bid||33.41 x 1300|
|Ask||33.98 x 800|
|Day's Range||33.30 - 34.24|
|52 Week Range||29.22 - 69.76|
|Beta (3Y Monthly)||3.19|
|PE Ratio (TTM)||9.39|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.91|
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for NKTR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 13. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold NKTR had net inflows of $2.49 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
It was a victory for stocks on Thursday, though not a decisive one. The 0.41% gain logged by the S&P 500 keeps it above some important technical support, but one rough day could still put the broad market into something of a tailspin.Walt Disney (NYSE:DIS) shares did more than their fair share of the heavy lifting, up 4.4% largely after Morgan Stanley predicted its planned streaming product, Disney+, would be even more successful than most investors have given it credit for. Restoration Hardware Holdings (NYSE:RH), also just called RH, logged one of the biggest wins on Thursday though, rallying more than 15% after topping its fiscal first quarter estimates.At the other end of the spectrum, Twitter (NYSE:TWTR) fell 3.1% after MoffettNathanson analyst Michael Nathanson suggested the recent strength made it a good time to take some profits.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone make for great trading options headed into the weekend though. Rather, it's the stock charts of Nektar Therapeutics (NASDAQ:NKTR), Vertex Pharmaceuticals (NASDAQ:VRTX) and Symantec (NASDAQ:SYMC) that present themselves as the top prospects. Here's why. Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals is no stranger to big swings in both directions. In fact, big swings are the norm. These aren't just sizeable, trade-worthy movements though. They're actually pretty predictable in terms of size and scope. The turns are taking shape pretty much where they should, even if VRTX is incapable of moving anywhere in a straight line. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 The stock's back at a well-established technical floor now, suggesting a rebound move is nigh. This revisit of a familiar floor does look a little bit different though, in that the stock's struggled to push up and off of it. It may be a clue that the bears are just waiting to deal a proverbial death blow. Click to Enlarge • The range in question is plotted with white lines on both stock charts, tracing the major highs and lows going all the way back to 2017.• Bolstering the case for a bounce here is the fact that the stochastic indicator is into oversold territory. That's not a condition that's been allowed to last long for Vertex Pharmaceuticals, but…• …zooming out shows that VRTX has been hugging the floor in question since April. It should have rebounded by now. One or two rough days could break the support, perhaps unleashing a wave of pent-up selling. Nektar Therapeutics (NKTR)Nektar Therapeutics was beaten so badly last year that traders have been wary of stepping back into it now. But, to its credit, at least the bleeding has stopped. The few bulls still testing the waters have even established a technical floor since late last year.There's a much bigger method to the madness though. That is, the selling has been slowly but surely ground to a halt, and the would-be buyers are establishing a base from which to carry the stock higher again. While there's still much work to be done, that work is being done. Click to Enlarge • The floor in question is plotted in yellow on both stock charts, tagging all the key lows going back to late December.• Zooming out to the weekly chart we can see shares of NKTR have already started to poke through falling resistance lines.• The key to, and signal of, a fully established breakout thrust is the next move above the white 200-day moving average line at $40.86 and the weekly chart's Chaikin line moving back above the zero level. Symantec (SYMC)In late March Symantec was featured as a name that had been range-bound for several weeks, and of the effort to push above a well-established ceiling at the time failed, a retreat back to the lower boundary of that range was likely.SYMC did indeed punch through that ceiling, though it was a flawed break. With a gap left in the rearview mirror, shares started to peel back in May and eventually made their way back to the support portion of the range anyway. Since kissing that floor late last month though, the bulls appear to have regrouped and are ready to make the trip back to the ceiling again. Click to Enlarge • The range in question is between $17.50 and $23.60, marked with red and yellow lines on both stock charts.• The weekly chart also shows an oversold stochastic indicator, which more often than not does point where Symantec has moved to an unsustainable extreme.• Curiously, though shares have yet to make a solid upward move, the weekly chart's rising Chaikin line suggests there's a lot more buying interest than selling pressure in place right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
MADRID and SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in clinical development for the treatment of autoimmune and other chronic inflammatory conditions. The data, which were presented during an oral session at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, show that NKTR-358 was safe and well-tolerated and led to a marked and selective dose-dependent expansion of T regulatory cells with no measurable effect on conventional CD4+ and CD8+ T cells (Tcons). NKTR-358 was discovered by Nektar and is being co-developed and commercialized in partnership with Eli Lilly and Company.
SAN FRANCISCO , June 11, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management ...
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Factors including acquisition activity, safe-haven buying, and favorable corporate news boosted these stocks.
Biotech stocks jumped Monday with Nektar Therapeutics, Iovance Therapeutics and Seattle Genetics stocks among the market leaders. All three rose on promising studies in cancer treatment.
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
were up 10.2% to $34.50 Monday after the company reported positive results from the clinical study of its melanoma treatment candidates. The Chicago-based company said that its two candidates, bempegaldesleukin and nivolumab, were showing positive signs in testing. The Stage IV melanoma patients enrolled in the ongoing PIVOT-02 study continue to experience both deepening and durability of response over time," said Jonathan Zalevsky, chief scientific officer at Nektar Therapeutics.
CHICAGO , June 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology ...
Overall, 14 stocks among the S&P 500 are down at least 50% from their 52-week highs. Are there bargains among them?
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.
SAN FRANCISCO, May 23, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will also lead development of several Nektar preclinical CNS assets.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Nektar Therapeutics (NASDAQ: NKTR ) is pretty good, but it's a total spec on oncology and pain. He would rather buy Novartis AG (NYSE: ...